Fitusiran

• CAT Number: I045372
• CAS Number: 1499251-18-1
• Molecular Weight: 16248.2 (AS: 7675 + SS: 8573.2)
• Purity: ≥95%

Fitusiran (Cat No.: I045372) is an investigational RNA interference (RNAi) therapeutic developed to treat hemophilia A and B, with or without inhibitors. It targets antithrombin (AT) mRNA in the liver, reducing antithrombin protein levels to rebalance hemostasis and promote thrombin generation. By lowering antithrombin, fitusiran enhances the blood clotting ability in individuals with deficient clotting factors. Administered subcutaneously, it offers the potential for once-monthly dosing. Fitusiran represents a novel, targeted approach to managing hemophilia, aiming to reduce bleeding episodes and improve patient quality of life.

Reference

[1]. Pasi KJ, et al. Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran-Results of the phase 1 inhibitor cohort. J Thromb Haemost. 2021;19(6):1436-1446.
[Content Brief]